Plasma proteins as prognostic biomarkers in radiotherapy treated head and neck cancer patients

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Background: Blood-based protein biomarkers can be a useful tool as pre-treatment prognostic markers, as they can reflect both variations in the tumor microenvironment and the host immune response. We investigated the influence of a panel of plasma proteins for the development of any failure defined as recurrent disease in the T-, N-, or M-site in HNSCC.

Methods: We used a multiplex bead-based approach to analyze 19 proteins in 86 HNSCC patients and 15 healthy controls. We evaluated the associations between the biomarkers, loco-regional failure, failure in the T-, N-, or M-site, overall survival (OS), p16 status, and hypoxia.

Results: In 41 p16 positive oropharynx cancer patients we identified a profile of biomarkers consisting of upregulation of IL-2, IL-4, IL-6, IL-8, eotaxin, GRO-a, and VEGF and downregulation of VEGFR-1 and VEGFR-2 with a significantly reduced risk of failure (p < 0.01). None of the individual proteins were associated with outcome.

Conclusion: The identified plasma profile potentially reflects an activated immune response in a subgroup of the p16 positive patients.

Original languageEnglish
JournalClinical and Translational Radiation Oncology
Pages (from-to)46-52
Number of pages7
Publication statusPublished - Feb 2017

    Research areas

  • Biomarkers, Circulating proteins, Head and neck cancer, Hypoxia, Immune response, Prognostic

See relations at Aarhus University Citationformats

ID: 129464675